Andreas Argyrides
Stock Analyst at Oppenheimer
(4.42)
# 293
Out of 5,090 analysts
117
Total ratings
51.49%
Success rate
21.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: Outperform | $8 → $9 | $6.50 | +38.46% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $21.69 | +24.48% | 9 | Nov 12, 2025 | |
| DYN Dyne Therapeutics | Maintains: Perform | $13 → $11 | $20.28 | -45.76% | 4 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $80.38 | +43.07% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $3.70 | +467.57% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $13.58 | +113.55% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $0.90 | +3,566.67% | 2 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $510 → $575 | $489.31 | +17.51% | 1 | Sep 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $12 → $15 | $5.68 | +164.08% | 2 | Sep 5, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Outperform | $19 → $20 | $4.88 | +310.26% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $39.83 | +53.15% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $6.38 | +9.72% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $1.06 | +183.02% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $34.41 | -62.22% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $1.59 | +151.57% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $7.02 | +1,182.05% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $2.09 | +330.62% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $205.44 | -11.90% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $14.90 | +597.99% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $3.33 | +170.27% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $9.93 | +91.34% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $21.68 | +33.76% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $13.16 | +59.57% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $22.26 | +906.29% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $23.99 | +137.60% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.66 | +953.27% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.50 | +1,916.54% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $53.40 | +31.09% | 6 | Aug 1, 2023 |
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $6.50
Upside: +38.46%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $21.69
Upside: +24.48%
Dyne Therapeutics
Nov 12, 2025
Maintains: Perform
Price Target: $13 → $11
Current: $20.28
Upside: -45.76%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $80.38
Upside: +43.07%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $3.70
Upside: +467.57%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $13.58
Upside: +113.55%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.90
Upside: +3,566.67%
United Therapeutics
Sep 5, 2025
Maintains: Outperform
Price Target: $510 → $575
Current: $489.31
Upside: +17.51%
MannKind
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $5.68
Upside: +164.08%
Abeona Therapeutics
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $4.88
Upside: +310.26%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $39.83
Upside: +53.15%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $6.38
Upside: +9.72%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.06
Upside: +183.02%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $34.41
Upside: -62.22%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $1.59
Upside: +151.57%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $7.02
Upside: +1,182.05%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.09
Upside: +330.62%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $205.44
Upside: -11.90%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $14.90
Upside: +597.99%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $3.33
Upside: +170.27%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $9.93
Upside: +91.34%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $21.68
Upside: +33.76%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $13.16
Upside: +59.57%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $22.26
Upside: +906.29%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $23.99
Upside: +137.60%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.66
Upside: +953.27%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.50
Upside: +1,916.54%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $53.40
Upside: +31.09%